dsm-firmenich is the first HMO manufacturer to apply and obtain approval for the four HMOs in this region
dsm-firmenich, a leading innovator in health, nutrition and beauty, announced that it has gained approval for an additional four human milk oligosaccharide (HMO) ingredients for use as nutritive substances in infant formula products in Australia and New Zealand. The approval follows the company’s successful application – submitted by Glycom A/S – to the Food Standards Australia New Zealand (FSANZ). dsm-firmenich is the first HMO manufacturer to apply and obtain approval for the four HMOs in this region.
Not only does the landmark approval authorise the use of additional science-backed ingredients with unique health benefits, but it paves the way for a new era of early-life nutrition solutions that are more closely matched to the function and composition of breastmilk. The four dsm-firmenich HMO ingredients evaluated by FSANZ were GlyCare™ 2’-fucosyllactose/difucosyllactose (2’-FL/DFL), GlyCare™ lacto-N-tetraose (LNT), GlyCare™ 6’-sialyllactose (6’-SL) sodium salt and GlyCare™ 3’-sialyllactose (3’-SL) sodium salt. FSANZ concluded that there were ‘no public health and safety concerns’ associated with incorporating these HMOs as nutritive substances in infant formula products, either individually or in combination, at the specified levels. Furthermore, a 15-month exclusive use period has been granted for all four GlyCare™ HMO products, commencing on the date of gazettal.
The FSANZ assessment also included an evaluation of the potential health benefits of the HMOs for infants. It verified that there is well-founded evidence that the HMOs elicit multiple positive effects when added to infant formula – including the promotion of beneficial gut microbiota, anti-pathogenic effects, suppression of inflammation support of immune responses and anti-genic memory.
